Keisha L. Gibson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Keisha L. Gibson has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dorey A. Glenn
University of North Carolina, Chapel Hill, North Carolina
4 shared publications - Maria Ferris
Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publications Debbie S. Gipson
Division of Nephrology and Hypertension University of North Carolina at Chapel Hill Chapel Hill
1 shared publication- Debbie S. Gipson
Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
1 shared publication Mary Anne Dooley
Division of Rheumatology University of North Carolina at Chapel Hill Chapel Hill North Carolina
1 shared publicationPanupong Hansrivijit
Chulalongkorn University, Bangkok, Thailand
1 shared publication
Latest Publications
- 15 November 2019
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 30 (12) , 2279-2280
Finding That Needle in the Haystack: Computable Phenotypes
Recruitment of patients for clinical trials is an area ready for innovation. At a time when there is measurable interest and support from industry sponsoring clinical trials in the glomerular disease space, connecting the right patients to the right trials as efficiently as possible is of great import. Harnessing data from electronic health records (EHRs) to streamline and personalize clinical trial recruitment using computable phenotypes has the potential to decrease the time and money associated with clinical trial setup. Indeed, global spending on clinical trial technology and services is expected to reach $69 billion per year by 2025.3 EHR-powered analytic tools are already commercialized for the purposes of protocol feasibility, cohort analysis, and study site identification.
- 15 November 2019
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 30 (12) , 2279-2280
Finding That Needle in the Haystack: Computable Phenotypes
Recruitment of patients for clinical trials is an area ready for innovation. At a time when there is measurable interest and support from industry sponsoring clinical trials in the glomerular disease space, connecting the right patients to the right trials as efficiently as possible is of great import. Harnessing data from electronic health records (EHRs) to streamline and personalize clinical trial recruitment using computable phenotypes has the potential to decrease the time and money associated with clinical trial setup. Indeed, global spending on clinical trial technology and services is expected to reach $69 billion per year by 2025.3 EHR-powered analytic tools are already commercialized for the purposes of protocol feasibility, cohort analysis, and study site identification.
- 15 April 2018
- Published by Springer Nature
- p. 1-10
ANCA-Associated Vasculitis, Pediatric
- 8 December 2015
- Published by Springer Nature in Pediatric Drugs
- Vol. 18 (1) , 25-29
Emerging Agents for the Management of Nephrotic Syndrome: Progress to Date
- 8 December 2015
- Published by Springer Nature in Pediatric Drugs
- Vol. 18 (1) , 25-29
Emerging Agents for the Management of Nephrotic Syndrome: Progress to Date
- Open Access
- 20 January 2015
- Published by S. Karger AG in Blood Purification
- Vol. 39 (1-3) , 105-109
Back to the Future: Therapies for Idiopathic Nephrotic Syndrome
Background: Roughly 20-40% of individuals with idiopathic nephrotic syndrome will fail to respond to standard therapies and have a high risk of progression to end stage kidney disease (ESKD). In the last 50 years, no new therapies have been approved specifically for the treatment of these individuals with recalcitrant disease. Summary: Recent in vitro, translational, and clinical studies have identified novel targets and pathways that not only expand our understanding of the complex pathophysiology of proteinuric disease but also provide an opportunity to challenge the tradition of relying on histologic classification of nephrotic diseases to make treatment decisions. Key Messages: The traditional methods of directing the care of individuals with nephrotic syndrome by histological classification or deciding second line therapies on the basis of steroid-responsiveness may soon yield customizing therapies based on our expanding understanding of molecular targets. Important non-immunologic mechanisms of widely used immunosuppressive therapies may be just as important in palliating proteinuric disease as proposed immunologic functions.
- 20 January 2015
- Published by S. Karger AG in Blood Purification
- Vol. 39 (1-3) , 105-109
Open AccessBack to the Future: Therapies for Idiopathic Nephrotic Syndrome
Background: Roughly 20-40% of individuals with idiopathic nephrotic syndrome will fail to respond to standard therapies and have a high risk of progression to end stage kidney disease (ESKD). In the last 50 years, no new therapies have been approved specifically for the treatment of these individuals with recalcitrant disease. Summary: Recent in vitro, translational, and clinical studies have identified novel targets and pathways that not only expand our understanding of the complex pathophysiology of proteinuric disease but also provide an opportunity to challenge the tradition of relying on histologic classification of nephrotic diseases to make treatment decisions. Key Messages: The traditional methods of directing the care of individuals with nephrotic syndrome by histological classification or deciding second line therapies on the basis of steroid-responsiveness may soon yield customizing therapies based on our expanding understanding of molecular targets. Important non-immunologic mechanisms of widely used immunosuppressive therapies may be just as important in palliating proteinuric disease as proposed immunologic functions.
- Open Access
- 1 December 2009
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (12) , 1962-1967
Predictors of Relapse and End Stage Kidney Disease in Proliferative Lupus Nephritis
Background and objectives: The prevalence and significance of remission and relapse in children, adolescents, and young adults with lupus nephritis in the United States are poorly understood. Patterns and predictors of disease progression in a southeastern U.S. pediatric cohort with severe lupus nephritis are presented. Design, settings, participants, & measurements: Individuals age 21 or less with kidney biopsy-proven lupus nephritis followed in the Glomerular Disease Collaborative Network were included. Cox regression models were used to evaluate predictors of relapse and end stage kidney disease (ESKD). Results: Seventy-three subjects with a mean age of 15.6 ± 3.4 yr were included. Five-year kidney survival was 77%. Complete and partial remission rates within 1 yr of induction therapy were 25 and 64%, respectively. Relapse and ESKD rates were similar between complete and partial responders. Relapse occurred in 35% of responders (complete or partial) in 45 ± 32 mo. Disease relapse was a predictor of ESKD (HR = 10.12, P < 0.0001). Treatment resistance was documented in African Americans more often than non-African Americans (eight versus 0; P = 0.03). ESKD HR associated with treatment resistance was 6.25, P < 0.002. Conclusions: Remission whether complete or partial is associated with improved kidney survival in children with lupus nephritis. Nephritis relapse is a strong predictor of progression to ESKD. Treatment resistance portends a high risk of ESKD and disproportionately affects African American children with lupus nephritis.
- 1 December 2009
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (12) , 1962-1967
Open AccessPredictors of Relapse and End Stage Kidney Disease in Proliferative Lupus Nephritis
Background and objectives: The prevalence and significance of remission and relapse in children, adolescents, and young adults with lupus nephritis in the United States are poorly understood. Patterns and predictors of disease progression in a southeastern U.S. pediatric cohort with severe lupus nephritis are presented. Design, settings, participants, & measurements: Individuals age 21 or less with kidney biopsy-proven lupus nephritis followed in the Glomerular Disease Collaborative Network were included. Cox regression models were used to evaluate predictors of relapse and end stage kidney disease (ESKD). Results: Seventy-three subjects with a mean age of 15.6 ± 3.4 yr were included. Five-year kidney survival was 77%. Complete and partial remission rates within 1 yr of induction therapy were 25 and 64%, respectively. Relapse and ESKD rates were similar between complete and partial responders. Relapse occurred in 35% of responders (complete or partial) in 45 ± 32 mo. Disease relapse was a predictor of ESKD (HR = 10.12, P < 0.0001). Treatment resistance was documented in African Americans more often than non-African Americans (eight versus 0; P = 0.03). ESKD HR associated with treatment resistance was 6.25, P < 0.002. Conclusions: Remission whether complete or partial is associated with improved kidney survival in children with lupus nephritis. Nephritis relapse is a strong predictor of progression to ESKD. Treatment resistance portends a high risk of ESKD and disproportionately affects African American children with lupus nephritis.
- 31 July 2009
- Published by Elsevier in Seminars in Nephrology
- Vol. 29 (4) , 360-369
Renal Manifestations of Systemic Illness in Children
- 31 July 2009
- Published by Elsevier in Seminars in Nephrology
- Vol. 29 (4) , 360-369
Renal Manifestations of Systemic Illness in Children